Search Results

China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field.

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.

· New U.S. subsidiary, NovAccel Isotopes Inc., established to support North American growth and long-term global supply ambitions in Ac-225 · Arnaud Lesegretain appointed Director and Chief Commercial and Business Officer of NovAccel, Inc., and CEO of NovAccel Isotopes Inc.; Takashi Mizukami appointed Director and Chief Strategy Officer

CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies aim to expand that advantage into a broader biotech ecosystem. The question remains whether Australia can support drug development at broader scale.

PATHORA will establish a U.S. organization focused on translational oncology and tissue-based drug development